REGN REGENERON PHARMACEUTICALS, ...

Nasdaq regeneron.com


$ 577.51 $ 8.88 (1.56 %)    

Friday, 17-Oct-2025 16:52:07 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 578.05
$ 570.35
$ 570.00 x 1
$ 578.05 x 1
$ 566.11 - $ 579.05
$ 475.76 - $ 998.41
745,708
na
61.27B
$ 0.72
$ 13.74
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-01-2025 06-30-2025 10-Q
2 04-29-2025 03-31-2025 10-Q
3 02-05-2025 12-31-2024 10-K
4 10-31-2024 09-30-2024 10-Q
5 08-01-2024 06-30-2024 10-Q
6 05-02-2024 03-31-2024 10-Q
7 02-05-2024 12-31-2023 10-K
8 11-02-2023 09-30-2023 10-Q
9 08-03-2023 06-30-2023 10-Q
10 05-04-2023 03-31-2023 10-Q
11 02-06-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-03-2022 06-30-2022 10-Q
14 05-04-2022 03-31-2022 10-Q
15 02-07-2022 12-31-2021 10-K
16 11-04-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 02-08-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-05-2020 06-30-2020 10-Q
22 05-05-2020 03-31-2020 10-Q
23 02-07-2020 12-31-2019 10-K
24 11-05-2019 09-30-2019 10-Q
25 08-06-2019 06-30-2019 10-Q
26 05-07-2019 03-31-2019 10-Q
27 02-07-2019 12-31-2018 10-K
28 11-06-2018 09-30-2018 10-Q
29 08-02-2018 06-30-2018 10-Q
30 05-03-2018 03-31-2018 10-Q
31 02-08-2018 12-31-2017 10-K
32 11-08-2017 09-30-2017 10-Q
33 08-03-2017 06-30-2017 10-Q
34 05-04-2017 03-31-2017 10-Q
35 02-09-2017 12-31-2016 10-K
36 11-04-2016 09-30-2016 10-Q
37 08-04-2016 06-30-2016 10-Q
38 05-05-2016 03-31-2016 10-Q
39 02-11-2016 12-31-2015 10-K
40 11-04-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 fda-unveils-first-experimental-drugs-under-fast-track-voucher-plan-to-cut-drug-review-times

The FDA launched a new voucher program to fast-track reviews, naming nine experimental drugs for cancer, diabetes, addiction, a...

 regenerons-libtayo-wins-positive-european-medicines-agency-opinion-for-high-risk-skin-cancer-treatment-after-surgery-and-radiation

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that the European Medicines Agency's (EMA) Committee for Medi...

Core News & Articles

https://www.fda.gov/news-events/press-announcements/fda-awards-first-ever-national-priority-vouchers-nine-sponsors

 eyepoint-pharmaceuticals-raises-capital-as-it-advances-lead-product-to-pivotal-study

EyePoint Pharmaceuticals outlines Phase 3 trials for Duravyu in diabetic macular edema, backed by $150 million in new funding.

 regeneron-to-share-new-oncology-data-at-esmo-2025-highlighting-patient-friendly-libtayo-every-6-week-dosing

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced new and updated data from its advancing oncology pipeline will be...

 canaccord-genuity-maintains-buy-on-regeneron-pharmaceuticals-maintains-850-price-target

Canaccord Genuity analyst John Newman maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and maintains $850 price ...

 regenerons-gene-therapy-shows-significant-gains-in-genetic-hearing-loss

Regeneron gene therapy for OTOF-related hearing loss shows rapid, sustained improvements, including normal hearing in some part...

 citigroup-maintains-buy-on-regeneron-pharmaceuticals-raises-price-target-to-660

Citigroup analyst Geoff Meacham maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target fro...

 reported-sunday-regenerons-db-oto-gene-therapy-yields-sustained-hearing-restoration-and-speech-perception-gains-in-otof-related-hearing-loss

Nearly all participants (11 of 12) experienced clinically meaningful hearing improvements, including three who achieved normal ...

 morgan-stanley-maintains-overweight-on-regeneron-pharmaceuticals-lowers-price-target-to-756

Morgan Stanley analyst Matthew Harrison maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and lowers the p...

 regenerons-libtayo-gains-fda-approval-to-reduce-recurrence-risk-in-skin-cancer-patients

FDA approves Regeneron's Libtayo for adults with high-risk cutaneous squamous cell carcinoma after surgery and radiation, b...

 regeneron-pharma-says-fda-approves-pd-1-inhibitor-libtayo-as-adjuvant-treatment-for-adult-patients-with-cscc-at-high-risk-of-recurrence-after-surgery-and-radiation

Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by...

 health-care-stocks-rally-nike-beats-the-street-whats-moving-markets-wednesday

Wall Street posts modest gains as shutdown begins and jobs data disappoints, but optimism around earnings and rate cuts keeps m...

 nvidia-amphenol-lockheed-martin-and-a-health-care-stock-on-cnbcs-final-trades

Nvidia surges past 52-week high, surpasses $4.5 trillion market cap as tech companies invest in AI. Regeneron and Amphenol name...

 fda-expands-use-of-regenerons-evkeeza-to-infants-with-rare-cholesterol-disorder

The U.S.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION